Jubilant Pharmova Ltd
JUBLPHARMABSE 530019PharmaceuticalsMkt cap ₹15,938 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹2,229 Cr
YoY +17.3%QoQ -2.6%
Net profit · Q1 FY27
₹56.40 Cr
YoY -45.0%QoQ -52.7%
Net margin · Q1 FY27
2.5%
-2.9 pts vs Q1 FY26
Net profit · FY26
₹398 Cr
YoY -52.5%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 2,229 | 2,290 | 2,123 | 1,966 | 1,901 | +17.3% |
| Other income | 19.90 | 23.70 | 20.50 | 9.80 | 12.00 | +65.8% |
| Total income | 2,249 | 2,314 | 2,143 | 1,976 | 1,913 | +17.6% |
| Profit before tax | 86.40 | 176 | 93.50 | 190 | 155 | -44.1% |
| Tax | 30.00 | 56.70 | 37.60 | 70.40 | 51.90 | -42.2% |
| Net profit | 56.40 | 119 | 55.80 | 120 | 103 | -45.0% |
| Net margin | 2.5% | 5.2% | 2.6% | 6.1% | 5.4% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 8,280 | 7,235 | 670 | 6,282 | 6,059 | +14.4% |
| Other income | 66.00 | 56.80 | 6.87 | 38.33 | 82.28 | +16.2% |
| Total income | 8,346 | 7,291 | 677 | 6,320 | 6,141 | +14.5% |
| Profit before tax | 614 | 981 | 14.64 | 15.53 | 640 | -37.4% |
| Tax | 217 | 144 | 9.78 | 92.66 | 217 | +50.1% |
| Net profit | 398 | 836 | 7.27 | -64.88 | 413 | -52.5% |
| Net margin | 4.8% | 11.6% | 1.1% | -1.0% | 6.8% |
BIC's take
We haven't covered Jubilant Pharmova Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:58 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.